Update on the diagnosis and treatment of prostate cancer

Curr Opin Oncol. 1998 May;10(3):244-52. doi: 10.1097/00001622-199805000-00012.

Abstract

Our understanding of the causes of prostate cancer and improvements in screening methodologies and risk assessment prior to definitive local therapy continue to be refined. The utility of hormone therapy has been further evaluated, both as adjuvant and neoadjuvant therapy with radiation therapy or radical prostatectomy, as well as for patients with more advanced disease. Finally, modest inroads continue to be made in the treatment and understanding of hormone-refractory prostate cancer.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adult
  • Aged
  • Androgens
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Biomarkers, Tumor / blood
  • Case-Control Studies
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Dietary Fats / adverse effects
  • Disease Susceptibility
  • Drug Resistance, Neoplasm
  • Hormone Antagonists / therapeutic use
  • Humans
  • Male
  • Mass Screening
  • Middle Aged
  • Neoplasm Proteins / blood
  • Neoplasms, Hormone-Dependent / diagnosis
  • Neoplasms, Hormone-Dependent / epidemiology
  • Neoplasms, Hormone-Dependent / etiology
  • Neoplasms, Hormone-Dependent / therapy
  • Neoplastic Syndromes, Hereditary / epidemiology
  • Neoplastic Syndromes, Hereditary / genetics
  • Oncogenes
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatectomy / adverse effects
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / etiology
  • Prostatic Neoplasms / therapy*
  • ROC Curve
  • Radioisotope Teletherapy / adverse effects
  • Risk Assessment
  • Salvage Therapy

Substances

  • Androgens
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Dietary Fats
  • Hormone Antagonists
  • Neoplasm Proteins
  • Prostate-Specific Antigen